Article
High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content.
JCO precision oncology - 1 Jan 2021
Meador Catherine B, Milan Marina S D, Hu Emmy Y, Awad Mark M, Rabin Michael S, Paweletz Cloud P, Hartmaier Ryan, Laus Gianluca, Oxnard Geoffrey R
Abstract excerpt
Plasma cell-free DNA (cfDNA) sequencing is a compelling diagnostic tool in solid tumors and has been shown to have high positive predictive value. However, limited assay sensitivity means that negative plasma genotyping, or the absence of detection of mutation of interest, still requires reflex tumor biopsy. METHODS: We analyzed two independent cohorts of patients with advanced non-small-cell lung cancer (NSCLC)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.